Start-up AliveCor can now detect a dangerous blood condition by monitoring heart signals, and the FDA has given it 'breakthrough status'
https://www.cnbc.com/2018/09/10/alivecor-gets-fda-breakthrough-status-for-bloodless-hyperkalemia-test.html
AliveCor, a Silicon Valley start-up that develops technology to monitor people's heart health, on Monday received "breakthrough device" designation from the U.S. Food and Drug Administration for developing a new way to detect high blood potassium levels without requiring any blood.
AliveCor worked with doctors at the Mayo Clinic, which is also an investor in the company, to develop a new technology that looks for a dangerous condition called hyperkalemia without requiring any blood from the patient. It instead looks for patterns in electrocardiograms (ECGs), which are essentially recordings of the electrical signals of the heart.
Start-up AliveCor can now detect a dangerous blood condition by monitoring heart signals, and the FDA has given it 'breakthrough status'
Sep 10, 2018, 9:32pm UTC
https://www.cnbc.com/2018/09/10/alivecor-gets-fda-breakthrough-status-for-bloodless-hyperkalemia-test.html
> AliveCor, a Silicon Valley start-up that develops technology to monitor people's heart health, on Monday received "breakthrough device" designation from the U.S. Food and Drug Administration for developing a new way to detect high blood potassium levels without requiring any blood.
> AliveCor worked with doctors at the Mayo Clinic, which is also an investor in the company, to develop a new technology that looks for a dangerous condition called hyperkalemia without requiring any blood from the patient. It instead looks for patterns in electrocardiograms (ECGs), which are essentially recordings of the electrical signals of the heart.